v3.25.3
Consolidated Statements of Changes in Equity - EUR (€)
€ in Millions
Total
Attributable to equity holders of Sanofi
Share capital
Additional paid-in capital
Treasury shares
Reserves and retained earnings
Stock options and other share-based payments
Other comprehensive income
Attributable to non-controlling interests
Beginning balance at Dec. 31, 2023 [1] € 74,353 € 74,040 € 2,530 € 313 € (1,184) € 67,499 € 4,944 € (62) € 313
Other comprehensive income for the period [1] 1,233 1,225       166   1,059 8
Net income for the period [1] 2,263 [2] 2,246       2,246     17
Comprehensive income [1] 3,496 [2] 3,471       2,412   1,059 25
Dividend paid out of earnings [1] (4,704) (4,704)       (4,704)      
Payment of dividends to non-controlling interests [1] (31)               (31)
Share repurchase program [1],[3] (302) (302)     (302)        
Share-based payment plans:                  
Exercise of stock options [1] 7 7   7          
Issuance of restricted shares and vesting of existing restricted shares [1]     3 (3) 115 (115)      
Value of services obtained from employees [1] 173 173         173    
Tax effects of share-based payments [1] 4 4         4    
Other changes arising from issuance of restricted shares [1],[4] 1 1       1      
Ending balance at Jun. 30, 2024 [1] 72,997 72,690 2,533 317 (1,371) 65,093 5,121 997 307
Other comprehensive income for the period [1] 1,199 1,185       (194)   1,379 14
Net income for the period [1] 3,355 3,314       3,314     41
Comprehensive income [1] 4,554 4,499       3,120   1,379 55
Payment of dividends to non-controlling interests [1] (13)               (13)
Reduction in share capital [1]     (12) (492) 530 (26)      
Share-based payment plans:                  
Exercise of stock options [1] 26 26 1 25          
Issuance of restricted shares and vesting of existing restricted shares [1]         1 (1)      
Employee share ownership plan [1] 154 154 4 150          
Value of services obtained from employees [1] 132 132         132    
Tax effects of share-based payments [1] 7 7         7    
Change in non-controlling interests without loss of control [1]   (1)       (1)     1
Ending balance at Dec. 31, 2024 [1] 77,857 77,507 2,526 0 (840) 68,185 5,260 2,376 350
Other comprehensive income for the period [1] (4,774) (4,736)       243   (4,979) (38)
Net income for the period [1] 5,837 5,812       5,812     25
Comprehensive income [1] 1,063 1,076       6,055   (4,979) (13)
Dividend paid out of earnings [1] (4,772) (4,772)       (4,772)      
Payment of dividends to non-controlling interests [1] (32)               (32)
Share repurchase program [1],[3] (3,988) (3,988)     (3,988)        
Reduction in share capital [1],[3]     (74)   3,868 (3,794)      
Taxes on Share Cancellations [1],[5] (15) (15)     (15)        
Share-based payment plans:                  
Exercise of stock options [1] 15 15 1 14          
Issuance of restricted shares and vesting of existing restricted shares [1]     3 (3)          
Value of services obtained from employees [1] 177 177         177    
Tax effects of share-based payments [1] (7) (7)         (7)    
Change in non-controlling interests without loss of control [1],[6] (34)               (34)
Other changes arising from issuance of restricted shares [1],[7] 15 15       15      
Ending balance at Jun. 30, 2025 [1] € 70,279 € 70,008 € 2,456 € 11 € (975) € 65,689 € 5,430 € (2,603) € 271
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] See Note B.8.2. (for amounts relating to 2024, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2024).
[4] For 2024, this line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.
[5] Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.
[6] This line comprises the impact of the derecognition of the non-controlling interests in Opella (see Note B.1.).
[7] For 2025, this line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.